Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

0.3998 -0.3002 (-42.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,070,310
Open 0.4500
Bid (Size) 0.3958 (16)
Ask (Size) 0.4070 (5)
Prev. Close 0.7000
Today's Range 0.3864 - 0.4980
52wk Range 0.2026 - 5.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-86.81%
-86.81%
1 Month
-16.25%
-16.25%
3 Month
-66.40%
-66.40%
6 Month
-63.85%
-63.85%
1 Year
-86.67%
-86.67%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock
Via InvestorPlace
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Via InvestorPlace
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
Via InvestorPlace
Why NKGen Biotech (NKGN) Stock Is Skyrocketing
Via Benzinga
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
From NKGen Biotech
Via GlobeNewswire
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
Privacy Policy  |  Terms of Use  |  MNG Corporate Site Map  |  Copyright